Annonce • Jun 03
Astrotech Corporation has filed a Follow-on Equity Offering in the amount of $24.492819 million. Astrotech Corporation has filed a Follow-on Equity Offering in the amount of $24.492819 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering Reported Earnings • May 14
Third quarter 2026 earnings released: US$2.25 loss per share (vs US$2.18 loss in 3Q 2025) Third quarter 2026 results: US$2.25 loss per share (further deteriorated from US$2.18 loss in 3Q 2025). Net loss: US$3.77m (loss widened 3.7% from 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings. Annonce • May 11
Astrotech Corporation Receives Ecac/Eu G1 Certification for Tracer 1000 System Astrotech Corporation announced that its 1st Detect TRACER 1000 system has achieved ECAC/EU G1 approval, meeting the highest European standards for aviation security. This approval reflects compliance with the European Civil Aviation Conference (ECAC) and European Commission requirements for trace detection systems, supporting enhanced security for airline passengers. The TRACER 1000 system is a field proven mass spectrometry solution with systems deployed in 16 countries worldwide. As the threat landscape evolves to include new, complex materials, the TRACER 1000 strengthens a layered security approach by providing the molecular certainty to help adapt to emerging risks, resolve alarms within operational timelines, and protect the traveling public and supply chain operations. New Risk • Mar 30
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 29% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (US$3.97m market cap). Minor Risk Revenue is less than US$5m (US$1.2m revenue). Reported Earnings • Feb 16
Second quarter 2026 earnings released: US$2.34 loss per share (vs US$2.45 loss in 2Q 2025) Second quarter 2026 results: US$2.34 loss per share (improved from US$2.45 loss in 2Q 2025). Net loss: US$3.93m (loss narrowed 2.0% from 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings. Reported Earnings • Nov 16
First quarter 2026 earnings released: US$2.07 loss per share (vs US$2.01 loss in 1Q 2025) First quarter 2026 results: US$2.07 loss per share (further deteriorated from US$2.01 loss in 1Q 2025). Net loss: US$3.47m (loss widened 5.7% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings. Annonce • Nov 01
Astrotech Corporation Appoints Scott Bartley as Interim Chief Financial Officer, Effective as of October 20, 2025 Astrotech Corporation announced that it has appointed Scott Bartley as Interim Chief Financial Officer (“CFO”) of the Company, effective as of October 20, 2025. Mr. Bartley, age 56, has served as a financial consultant since 2011, including roles as Chief Financial Officer and controller for both public and private companies where he provided detailed accounting, reporting, fundraising and audit support. Mr. Bartley has served as a consultant at Bridgepoint Consulting since 2018. Previously, Mr. Bartley was owner and managing director of Tolarus Partners from 2013 to 2015 and Helix Advisors from 2011 to 2013 and again from 2015 to 2018, providing contract Chief Financial Officer and valuation services to technology, manufacturing and pharmaceutical clients. Mr. Bartley was Chief Financial Officer of Westlake Securities, a broker dealer from 2008 to 2011. Prior to Westlake Securities, Mr. Bartley was an Assurance Senior Manager at Deloitte & Touche, LLP. Mr. Bartley is a Certified Public Accountant and Certified Valuation Analyst. He received a Bachelor of Business Administration and Master of Professional Accounting degree from the University of Texas at Austin. Annonce • Oct 29
Astrotech Corporation, Annual General Meeting, Dec 12, 2025 Astrotech Corporation, Annual General Meeting, Dec 12, 2025. Location: 1817 w braker lane, suite 400, austin United States Reported Earnings • Sep 26
Full year 2025 earnings released: US$8.32 loss per share (vs US$7.12 loss in FY 2024) Full year 2025 results: US$8.32 loss per share (further deteriorated from US$7.12 loss in FY 2024). Net loss: US$13.9m (loss widened 19% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 28% per year, which means it is performing significantly worse than earnings. Annonce • Aug 19
Astrotech Corporation Appoints Nihanth Badugu as Chief Operating Officer, Effective August 13, 2025 Astrotech Corporation announced that it has appointed Nihanth Badugu as Chief Operating Officer of the Company. Mr. Badugu’s appointment is effective as of August 13, 2025. Mr. Badugu, age 37, has served as Astrotech’s Director of Program Management since August 2023, where he led initiatives that enhanced operational efficiency and ensured timely program completion. Mr. Badugu brings to Astrotech extensive experience from the chemical manufacturing and consulting industries. Prior to Astrotech, he held the role of NPI Program Manager at Thermo Fisher Scientific, from 2020 to 2023, where he led the launch of COVID-19 diagnostic products. Mr. Badugu also held the role of Senior Program Manager at PVA Consulting Group, from 2017 to 2020. Mr. Badugu’s track record in program management and operational leadership positions him as a key contributor to Astrotech’s growth strategy. Mr. Badugu holds a Bachelor of Science degree from York University. Annonce • May 29
Astrotech Corporation Appoints Jennifer Cañas as Chief Financial Officer Effective May 22, 2025 Astrotech Corporation announced that it has appointed Jennifer Cañas as Chief Financial Officer of the Company, effective May 22, 2025. Ms. Cañas has served as the Company’s Corporate Controller since June 2022. She brings over 20 years of experience in senior financial roles. Prior to joining Astrotech, Ms. Cañas served as the Controller of The Texas Water Company, formerly SJWTX from 2018 to 2022. In 2008, Ms. Cañas founded a small business tax and financial advisory firm, where she served as a Controller Consultant until 2022. She has extensive experience at Big Four accounting firm, PricewaterhouseCoopers, and mid-size accounting firms. Ms. Cañas is a Certified Public Accountant. She received her Bachelor of Science degree in accounting from the University of Houston – Clear Lake where she graduated with honors, Cum Laude. Reported Earnings • May 15
Third quarter 2025 earnings released: US$2.18 loss per share (vs US$1.93 loss in 3Q 2024) Third quarter 2025 results: US$2.18 loss per share (further deteriorated from US$1.93 loss in 3Q 2024). Net loss: US$3.63m (loss widened 15% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings. New Risk • Apr 13
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.99m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 10% per year over the past 5 years. Revenue is less than US$1m (US$419k revenue). Market cap is less than US$10m (US$9.99m market cap). Annonce • Mar 10
Astrotech Corporation Announces the Launch of Its Enhanced TRACER 1000 Narcotics Trace Detector from Its 1St Detect Subsidiary Astrotech Corporation announced the launch of its enhanced TRACER 1000 Narcotics Trace Detector from its 1st Detect subsidiary. This innovative mobilized mass spectrometer is specifically configured to screen for the full range of synthetic opiates and novel psychoactive substances ("NPS"), delivering accuracy and speed to counter the global drug crisis. The latest iteration of the TRACER 1000 NTD represents a significant leap forward in portable trace detection. With the increasing prevalence of dangerous and ever-evolving synthetic drugs, this advanced detection tool could be an important asset for law enforcement, border security, first responders, and public health agencies worldwide. Designed for ease of use, portability, and high sensitivity, the TRACER 1 NTD has several key advantages, including: Full-Spectrum Screening: Identifies a broad range of synthetic opioids and NPS, including fentanyl and its analogs. User-Friendly Interface: Intuitive operation minimizes training time for security and enforcement personnel. The TRACER 1000 NTD is available now and ready for deployment across various security, public safety, and healthcare sectors. Reported Earnings • Feb 16
Second quarter 2025 earnings released: US$2.45 loss per share (vs US$1.62 loss in 2Q 2024) Second quarter 2025 results: US$2.45 loss per share (further deteriorated from US$1.62 loss in 2Q 2024). Net loss: US$4.01m (loss widened 52% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings. Annonce • Jan 24
Astrotech Corporation Appoints Ryan Polk as Interim Chief Financial Officer Astrotech Corporation and its Board of Directors have appointed Ryan Polk to serve as interim Chief Financial Officer. Mr. Polk will assume the Company’s Chief Financial Officer role effective February 14, 2025 on an interim basis. He has held Chief Financial Officer positions at both public and private entities and brings experience in scaling companies through both organic growth and acquisition. Board Change • Jan 02
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Director Eric Stober was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. New Risk • Nov 26
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.0% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.1% increase in shares outstanding). Revenue is less than US$5m (US$1.3m revenue). Market cap is less than US$100m (US$12.7m market cap). Reported Earnings • Nov 14
First quarter 2025 earnings released: US$2.01 loss per share (vs US$1.79 loss in 1Q 2024) First quarter 2025 results: US$2.01 loss per share (further deteriorated from US$1.79 loss in 1Q 2024). Net loss: US$3.28m (loss widened 13% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings. Annonce • Oct 25
Astrotech Corporation, Annual General Meeting, Dec 13, 2024 Astrotech Corporation, Annual General Meeting, Dec 13, 2024. Location: 2105 donley drive, suite 100, texas 78758, austin United States New Risk • Sep 22
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.0% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Revenue is less than US$5m (US$1.7m revenue). Market cap is less than US$100m (US$12.9m market cap). Reported Earnings • Sep 20
Full year 2024 earnings released: US$7.12 loss per share (vs US$5.95 loss in FY 2023) Full year 2024 results: US$7.12 loss per share (further deteriorated from US$5.95 loss in FY 2023). Net loss: US$11.7m (loss widened 21% from FY 2023). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. New Risk • Sep 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.3% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Revenue is less than US$5m (US$2.0m revenue). Market cap is less than US$100m (US$13.2m market cap). Reported Earnings • May 15
Third quarter 2024 earnings released: US$1.93 loss per share (vs US$1.47 loss in 3Q 2023) Third quarter 2024 results: US$1.93 loss per share (further deteriorated from US$1.47 loss in 3Q 2023). Net loss: US$3.15m (loss widened 33% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. Annonce • Mar 26
Astrotech Introduces the "Gold Standard" of Mass Spectrometry into Narcotic Trace Detector Astrotech Corporation and its wholly owned subsidiary, 1st Detect Corporation, announced that it is currently accepting orders for the Tracer 1000 Narcotics Trace Detector (NTD). The TRACER 1000 NTD is a high-performance laboratory instrument capable of rapid detection of trace levels of narcotic compounds in seconds. Currently, the Company's Tracer 1000 Explosive Trace Detector (ETD) is now found in multiple locations in 14 countries throughout the world. The NTD provides a ruggedized platform that can be applied across various markets including airports, border security, checkpoint, cargo, and infrastructure security, correctional facilities, military, and law enforcement. The Astrotech Mass Spectrometer Technology™? (AMS Technology) drives the breakthrough TRACER 1000, as the first certified ETD to employ mass spectrometry as a trace detection security solution. As stated by Dr. Laura Parker, R&D Program Manager from the U.S. Department of Homeland Security, mass spectrometers are the "gold standard" of chemical detection1. The TRACER 1000 is the only mass spectrometry-based ETD to have received European Civil Aviation Conference certification for both checkpoint and cargo security. Reported Earnings • Feb 14
Second quarter 2024 earnings released: US$1.62 loss per share (vs US$1.50 loss in 2Q 2023) Second quarter 2024 results: US$1.62 loss per share (further deteriorated from US$1.50 loss in 2Q 2023). Net loss: US$2.64m (loss widened 9.2% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings. Annonce • Dec 13
Astrotech Corporation Announces Exciting New Technology Application Astrotech Corporation announces formation of a wholly owned subsidiary Pro-Control Inc. (“Pro-Control”) and has entered into an exclusive license to use the ATi Mass Spectrometer Technology for chemical manufacturing process control applications. Pro-Control is announcing the introduction of its proprietary Pro-Control Maximum Value ProcessTM (“Pro-Control MVPTM”) and the Pro-Control-1000TM mass spectrometer designed to test, measure and increase potency, purity and weight yields in the chemical manufacturing processes, delivering value to customers by facilitating improved yields, which believe will lead to an overall increase in profitability. Pro-Control MVPTM uses advanced mass spectrometer instrumentation to monitor and control the fractional distillation of bulk chemicals using real-time in-process samples. Pro-Control MVPTM provides the vital spectral qualitative and quantitative data needed to control the distillation parameters (temps, flow, speed, pressure) while significantly improving efficiency. The Pro-Control MVPTM rapid test can take up to 20 tests per hour providing ideal testing conditions to greatly increase efficiency. Annonce • Nov 29
Astrotech Corporation Presents the First Process Control System for Cannabinoid Oil Distillation Systems Astrotech Corporation and its wholly owned subsidiary, AgLAB Inc., announce the presentation of the AgLAB Maximum Value ProcessTM (“MVPTM”) at MJBizCon. This process is a revolutionary process control system proven to increase the potency of ending-weight yields and increase revenue by an average of 32%. MVPTM uses AgLAB’s proprietary mass spectrometer and testing method to provide real-time data and feedback, allowing distillers to adjust the parameters (temperature, feed-rate, pressure) and optimize the quality and quantity of each batch of oil. MVPTM is the fastest and most accurate testing method available, providing up to 20 tests per hour and ensuring optimal continuous processing. MVPTM is compatible with any of the thin-film, short-path, Molecular Distillation Systems (MDS) operating under high vacuum. MDS vacuum systems introduce challenges such as vacuum leaks leading to variations in pressures and temperatures, which can result in losses of 20% to 55% in revenue. MVPTM solves these challenges by providing a quick and easy test that recovers these losses and delivers higher potencies, better color, and an average of 32% increase in yield. MVPTM will be showcased at the AgLAB Booth, Nov. 28 to Dec. 1, 2023, at MJBizCon, the No. 1 global hemp and cannabis business conference and tradeshow. Held annually at the Las Vegas Convention Center, MJBizCon features over 1,400 exhibitors and more than 30,000 industry executives from around the world. Reported Earnings • Nov 16
First quarter 2024 earnings released: US$1.79 loss per share (vs US$1.57 loss in 1Q 2023) First quarter 2024 results: US$1.79 loss per share (further deteriorated from US$1.57 loss in 1Q 2023). Net loss: US$2.91m (loss widened 15% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. Annonce • Nov 02
Astrotech Corporation, Annual General Meeting, Dec 15, 2023 Astrotech Corporation, Annual General Meeting, Dec 15, 2023, at 09:00 Central Standard Time. Location: 2105 Donley Drive Suite 100 Austin Texas United States Agenda: To consider elect five director nominees to serve as directors until the 2024 annual meeting of stockholders;to consider to ratify the appointment of RBSM LLP as our Independent Registered Public Accounting Firm for the fiscal year ending June 30, 2024;to consider to transact such other business as may properly come before the Annual Meeting and any related adjournments or postponements. Reported Earnings • Sep 29
Full year 2023 earnings released: US$5.95 loss per share (vs US$5.24 loss in FY 2022) Full year 2023 results: US$5.95 loss per share (further deteriorated from US$5.24 loss in FY 2022). Net loss: US$9.64m (loss widened 16% from FY 2022). Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings. Reported Earnings • May 14
Third quarter 2023 earnings released: US$1.47 loss per share (vs US$1.32 loss in 3Q 2022) Third quarter 2023 results: US$1.47 loss per share (further deteriorated from US$1.32 loss in 3Q 2022). Net loss: US$2.38m (loss widened 13% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 15
Second quarter 2023 earnings released: US$1.50 loss per share (vs US$1.38 loss in 2Q 2022) Second quarter 2023 results: US$1.50 loss per share (further deteriorated from US$1.38 loss in 2Q 2022). Net loss: US$2.42m (loss widened 11% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings. Annonce • Feb 07
Astrotech Appoints Thomas B. Pickens III as Chief Technology Officer Astrotech Corporation announced that its Board of Directors has appointed Thomas B. Pickens III to serve as its Chief Technology Officer (“CTO”) in conjunction with his current duties as Chief Executive Officer. In 2017, Mr. Pickens oversaw the Company’s evaluation of possibilities around a point-of-care mass-spec breath analysis device using the AMS Technology. Due to the worldwide effects of the COVID-19 pandemic, the Company formed BreathTech Corporation and began the commercialization of the BreathTest-1000™ COVID-19 rapid detection device. During the development of this product, Mr. Pickens has been a valued team member in the discovery and development of the method to detect the compounds associated with COVID-19 lung infections. Moreover, Mr. Pickens led the effort that found and hired Dr. Karim Sirgi, MD, MBA and FCAP as BreathTech’s Chief Science Officer. Dr. Sirgi is helping lead clinical trial and in vivo sample collection efforts with Cleveland Clinic and Mountain View Clinical Research. Mr. Pickens also leads the team that is developing applications for the AMS Technology in the distillation of essential oils using molecular distillation systems, including the manufacturing of hemp and cannabis oils. Mr. Pickens has been instrumental in process to accurately qualify and quantify chemical compounds using technology. To commercialize this application, Mr. Pickens brought to the team Joe Levinthal, a distillation veteran with extensive mass spectrometry experience, as the Chief Science Officer at AgLAB Inc. Annonce • Feb 02
Astrotech Corporation Appoints Bob Mcfarland to Board of Directors Astrotech Corporation announced that it has increased the size of its Board of Directors from four to five directors and has appointed Bob McFarland as a director of the Company. Mr. McFarland brings to Astrotech’s Board extensive executive management experience with domestic and international enterprises, with a focus on information technology. Mr. McFarland served as an Assistant Secretary for Information and Technology and Chief Information Officer at the Department of Veterans Affairs (“VA”) from January 2004 through his retirement in 2006. In this role, he advised the Secretary of Veterans Affairs on matters pertaining to acquisition and management of IT systems. He was also responsible for overseeing operation of the VA’s computer systems and telecommunication networks for medical information, veterans’ benefits payments, life insurance programs, and financial management systems. Prior to his tenure at the VA, Mr. McFarland served as Vice President of Governmental Relations for Dell Computer Corporation. He joined Dell in 1996 as Vice President and General Manager of the Federal Business segment. He held several senior executive positions at Dell, including managing its global segment, large corporate accounts, and government sector. Under his leadership, Dell became a leading supplier of computer systems to the federal government. In 1998, Mr. McFarland was named to the “Federal 100,” a joint government and industry award designating the top 100 executives in the federal marketplace. Mr. McFarland currently serves on the Board of Advisors of Veterans Advantage. He has previously served as Director for Xplore Technologies Corporation, CSIdentity Corporation, Ezenia! Inc., and Isothermal Systems Research Inc. Mr. McFarland has a Bachelor of Science Degree in Business Management from LeTourneau University in Longview, Texas. Reported Earnings • Nov 16
First quarter 2023 earnings released: US$0.052 loss per share (vs US$0.043 loss in 1Q 2022) First quarter 2023 results: US$0.052 loss per share (further deteriorated from US$0.043 loss in 1Q 2022). Net loss: US$2.53m (loss widened 25% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 11
First quarter 2023 earnings released: US$0.052 loss per share (vs US$0.043 loss in 1Q 2022) First quarter 2023 results: US$0.052 loss per share (further deteriorated from US$0.043 loss in 1Q 2022). Net loss: US$2.53m (loss widened 25% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 15
Full year 2022 earnings released: US$0.17 loss per share (vs US$0.35 loss in FY 2021) Full year 2022 results: US$0.17 loss per share. Net loss: US$8.33m (loss widened 9.6% from FY 2021). Board Change • Jul 31
High number of new directors Director Jim Becker was the last director to join the board, commencing their role in 2022. Reported Earnings • May 13
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Third quarter 2022 results: US$0.044 loss per share (up from US$0.13 loss in 3Q 2021). Net loss: US$2.10m (loss narrowed 13% from 3Q 2021). Revenue missed analyst estimates by 17%. Earnings per share (EPS) also missed analyst estimates by 8.3%. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 8 highly experienced directors. Independent Director Tom Wilkinson was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Feb 12
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2022 results: US$0.046 loss per share (up from US$0.10 loss in 2Q 2021). Net loss: US$2.18m (loss widened 34% from 2Q 2021). Revenue missed analyst estimates by 17%. Earnings per share (EPS) exceeded analyst estimates by 8.3%. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 13
First quarter 2022 earnings released: US$0.043 loss per share (vs US$0.27 loss in 1Q 2021) First quarter 2022 results: Net loss: US$2.03m (loss narrowed 3.9% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings. Board Change • Nov 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 8 highly experienced directors. Independent Director Tom Wilkinson was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Sep 21
Full year 2021 earnings released: US$0.35 loss per share (vs US$1.31 loss in FY 2020) Full year 2021 results: Net loss: US$7.60m (loss narrowed 8.5% from FY 2020). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings. Reported Earnings • May 16
Third quarter 2021 earnings released: US$0.13 loss per share (vs US$0.34 loss in 3Q 2020) Third quarter 2021 results: Net loss: US$2.40m (loss widened 16% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Executive Departure • Apr 22
COO & VP has left the company On the 20th of April, Rajesh Mellacheruvu's tenure as COO & VP ended after 6.2 years in the role. As of December 2020, Rajesh personally held 70.50k shares (US$125k worth at the time). A total of 2 executives have left over the last 12 months. Is New 90 Day High Low • Mar 09
New 90-day low: US$1.71 The company is down 8.0% from its price of US$1.85 on 08 December 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Aerospace & Defense industry, which is up 2.0% over the same period. Reported Earnings • Feb 18
Second quarter 2021 earnings released: US$0.10 loss per share (vs US$0.35 loss in 2Q 2020) Second quarter 2021 results: Net loss: US$1.62m (loss narrowed 22% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Feb 06
New 90-day high: US$2.60 The company is up 49% from its price of US$1.74 on 06 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Aerospace & Defense industry, which is up 13% over the same period. Reported Earnings • Nov 14
First quarter 2021 earnings released: US$0.27 loss per share The company reported a solid first quarter result with improved revenues and control over expenses, though losses increased. First quarter 2021 results: Revenue: US$140.0k (up US$139.0k from 1Q 2020). Net loss: US$2.11m (loss widened 2.1% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.